Posted by Michael Wonder on 08 Dec 2023
Phathom Pharmaceuticals announces FDA acceptance for filing of Voquenza (vonoprazan) tablets new drug application for the treatment of heartburn associated with non-erosive GERD
6 December 2023 - July 19, 2024 PDUFA target action date assigned by the FDA.
Phathom Pharmaceuticals announced today the FDA has accepted for review the company’s NDA for VOQUEZNA (vonoprazan) as a daily treatment of heartburn associated with Non-Erosive gastroesophageal reflux disease (GERD) in adults.
